HomeCompareRYB vs PFE

RYB vs PFE: Dividend Comparison 2026

RYB yields 270.60% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RYB wins by $765.41M in total portfolio value
10 years
RYB
RYB
● Live price
270.60%
Share price
$0.74
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$765.46M
Annual income
$443,239,509.84
Full RYB calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — RYB vs PFE

📍 RYB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRYBPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RYB + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RYB pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RYB
Annual income on $10K today (after 15% tax)
$23,000.95/yr
After 10yr DRIP, annual income (after tax)
$376,753,583.36/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, RYB beats the other by $376,731,263.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RYB + PFE for your $10,000?

RYB: 50%PFE: 50%
100% PFE50/50100% RYB
Portfolio after 10yr
$382.75M
Annual income
$221,632,884.28/yr
Blended yield
57.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

RYB
Analyst Ratings
2
Hold
1
Sell
Consensus: Hold
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RYB buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRYBPFE
Forward yield270.60%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$765.46M$49.6K
Annual income after 10y$443,239,509.84$26,258.71
Total dividends collected$732.01M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold

Year-by-year: RYB vs PFE ($10,000, DRIP)

YearRYB PortfolioRYB Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$37,760$27,059.94$9,153$693.39+$28.6KRYB
2$135,897$95,493.60$8,593$849.25+$127.3KRYB
3$466,604$321,194.63$8,336$1,066.78+$458.3KRYB
4$1,529,947$1,030,680.46$8,437$1,384.80+$1.52MRYB
5$4,795,450$3,158,406.58$9,013$1,875.40+$4.79MRYB
6$14,383,166$9,252,034.63$10,306$2,680.72+$14.37MRYB
7$41,324,531$25,934,543.97$12,820$4,101.38+$41.31MRYB
8$113,855,569$69,638,320.37$17,673$6,826.70+$113.84MRYB
9$301,138,076$179,312,617.43$27,543$12,591.86+$301.11MRYB
10$765,457,251$443,239,509.84$49,560$26,258.71+$765.41MRYB

RYB vs PFE: Complete Analysis 2026

RYBStock

RYB Education, Inc. provides early childhood education service in the People's Republic of China. The company offers play-and-learn centers services for the joint participation of 0-6-year-old children and their adult family members to promote children's development, foster bonding with family, and prepare them for their entry into kindergartens and primary schools; operates student care centers; and course content, training, support and guidance, and other services to franchisees and licensees. It also develops and sells educational products and services; distributes merchandise, such as teaching aids, educational toys, at-home educational products, and school uniforms through franchisees and other business partners, as well as directly to a market of families. In addition, the company operates Qingtian Youpin, an e-commerce platform for maternity and children's products. As of December 31, 2021, it operated 1,017 play-and-learn centers and 54 student care centers. The company was formerly known as Top Margin Limited and changed its name to RYB Education, Inc. in June 2017. RYB Education, Inc. was founded in 1998 and is based in Beijing, China.

Full RYB Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this RYB vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RYB vs SCHDRYB vs JEPIRYB vs ORYB vs KORYB vs MAINRYB vs JNJRYB vs MRKRYB vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.